Biogen weekly recap cites LEQEMBI Pen Japan approval and Phase III data
The weekly recap says Biogen is expanding beyond neuroscience into immunology, kidney disease and ophthalmology, with late-stage Phase III readouts and potential launches starting next quarter, plus Japan approval for the LEQEMBI Pen enabling at-home dosing and strong Phase III VALIANT kidney data.